Immunotherapy of multisystem inflammatory syndrome in children (MIS-C) following COVID-19 through mesenchymal stem cells


Posted: 2021-10-09 19:00:00
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new type of coronavirus causing coronavirus 2019 (COVID-19) that was first observed in Wuhan, China, in Dec. 2019. An inflammatory immune response targeting children appeared during the pandemic, which was associated with COVID-19 named multisystem inflammatory syndrome in children (MIS-C). Characteristics of MIS-C include the classic inflammation findings, multi-organ dysfunction, and fever as the cardinal feature. Up to now, no specific therapy has been identified for MIS-C. Currently, considerable progress has been obtained in the MIS-C treatment by cell therapy, specially Mesenchymal stem cells (MSCs). Unique properties have been reported for MSCs, such as various resources for purification of cell, high proliferation, self-renewal, non-invasive procedure, tissue regenerator, multidirectional differentiation, and immunosuppression. As indicated by a recent clinical research, MSCs have the ability of reducing disease inflammation and severity in children with MIS-C. In the present review study, the benefits and characteristics of MSCs and exosomes are discussed for treating patients with MIS-C. Keywords: Coronavirus disease 2019; Exosomes; MIS-C; Mesenchymal stem cell.

参考サイト PubMed: covid-19



バイオクイックニュース日本語版:COVID-19特集

バイオクイックニュース日本語版
12月 07, 2020 バイオアソシエイツ

COVID-19療法で間葉系幹細胞や回復期血漿を用いる際は、エクソソームの関与を考慮しなければならないとの提言

2020年11月14日にThe Journal of Extracellular Vesiclesのオンラインで公開されたオープンアクセスの論文で、イェール大学医学部内科リウマチ学および臨床免疫学部門医学病理学教授のPhilip Askenase医学博士(写真)は、重度の COVID-19 患者の場合、間葉系幹細胞(MSC)由来の エキソソーム…

ゲスト 629人 と メンバー 6人 がオンラインです